The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria Alison McGill 1 , Adrian Frank 1 , Nicola Emmett, Douglas M. Turnbull, Mark A. Birch-Machin and Nick J. Reynolds 2 Skin and Environmental Interactions Research Group, School of Clinical and Laboratory Sciences, and Mitochondrial Research Group, School of Neurology, Neurobiology, and Psychiatry, Medical School, University of Newcastle upon Tyne, UK 2 Correspondence: Dermatological Sciences, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. E-mail: n.j.reynolds@ncl.ac.uk <h3>SPECIFIC AIMS</h3> The goals of this work were to investigate 1) the effects of the anti-psoriatic drug anthralin on mitochondrial function and the activity of individual respiratory chain complexes in living human keratinocytes; and 2) whether anthralin might be acting on mitochondria to induce keratinocyte apoptosis, thus contributing to its therapeutic efficacy in clearing psoriatic plaques. <h3>PRINCIPAL FINDINGS</h3> 1. Anthralin induces disruption of ΔΨ m in human keratinocytes Anthralin induced a dose and time-dependent reduction of ΔΨ m (measured as the fluorescence intensity ratio of JC-1 red J-aggregates/green monomers) in human keratinocytes (<h3>Fig. 1</h3> A). Mitochondria, highlighted by fluorescent JC-1 J-aggregates, appeared swollen, rounded with loss of their
/lp/fed-of-american-socs-for-experimental-biology/the-anti-psoriatic-drug-anthralin-accumulates-in-keratinocyte-07gk2RCWQ6